Pharmaceutical

European Commission greenlights Mirati’s Krazati in KRAS-mutated NSCLC 

Mirati filed a marketing authorisation application to the EMA for Krazati for patients within this indication in May 2022.

Jan 11, 2024 - 18:00
European Commission greenlights Mirati’s Krazati in KRAS-mutated NSCLC 
Mirati filed a marketing authorisation application to the EMA for Krazati for patients within this indication in May 2022.
Read the original article

Tags:

Previous Article

FDA approves import of French drug for syphilis amidst wider drug shortages

Next Article

Eli Lilly and Innovent’s obesity drug mazdutide achieves positive Phase III results

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Colorado pioneered legal marijuana without sparking ‘reefer madness,’ but challenges lie ahead

STAT+: Colorado pioneered legal marijuana without spark...

Oct 30, 2023

The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market

The VPAS fallout continues – Celltrion pulls high-profi...

Jul 3, 2023

Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise

Listen: ESMO highlights, Roivant’s big deal, & biotech ...

Oct 26, 2023